الاتحاد الأوروبي - الإسبانية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuficiencia cardíaca - agentes que actúan sobre el sistema renina-angiotensina - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

الاتحاد الأوروبي - الألمانية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - herzfehler - angiotensin-ii-antagonisten, andere kombinationen, mittel, die auf das renin-angiotensin-system - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - الألمانية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - herzfehler - wirkstoffe, die auf das renin-angiotensin-system einwirken - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

الاتحاد الأوروبي - البرتغالية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuficiência cardíaca - a angiotensina ii, os antagonistas, outras combinações, os agentes que actuam no sistema renina-angiotensina - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - الهولندية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - hartfalen - angiotensine ii-antagonisten, andere combinaties van geneesmiddelen die op het renine-angiotensine systeem - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - الهولندية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - hartfalen - middelen die werken op het renine-angiotensinesysteem - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - arrêt cardiaque - l'angiotensine ii antagonistes, d'autres combinaisons, les agents agissant sur le système rénine-angiotensine - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - arrêt cardiaque - agents agissant sur le système rénine-angiotensine - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - heart failure - angiotensin ii antagonists, other combinations, agents acting on the renin-angiotensin system - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - heart failure - agents acting on the renin-angiotensin system - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).